Last reviewed · How we verify
butazolamide
butazolamide is a drug. It is currently in unknown development.
Butazolamide works by inhibiting the enzyme carbonic anhydrase, which plays a crucial role in maintaining acid-base balance in the body.
Butazolamide is a small molecule drug with unknown target and drug class. It is not FDA approved for any indications. The commercial status of butazolamide is unclear, and it may be off-patent. Butazolamide's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand its mechanism of action and potential therapeutic applications.
At a glance
| Generic name | butazolamide |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a leaky faucet - carbonic anhydrase helps regulate the amount of acid in the body by controlling the flow of fluids. Butazolamide blocks this enzyme, which can help reduce the amount of acid in the body and alleviate symptoms of certain conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- butazolamide CI brief — competitive landscape report
- butazolamide updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about butazolamide
What is butazolamide?
How does butazolamide work?
What development phase is butazolamide in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing